Results 101 to 110 of about 124,423 (315)
, 2011 The indications for allogeneic stem cell transplantation (SCT) in Acute Myeloid Leukemia (AML) represent a real challenge due to the clinical and genetic heterogeneity of the disorder.
Hartwig, Maite +5 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Vincristine‐induced peripheral neuropathy (VIPN) is a common side effect in children and adolescents treated with vincristine. Assessing VIPN, especially in young children, is challenging due to a lack of sensitive tools. This limits our understanding of the nature and risk factors of VIPN. This study aimed to investigate neurofilament light chain
Peter Erik Lotko Pontoppidan +8 more
wiley +1 more source
Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients
British Journal of Clinical Pharmacology, EarlyView.Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen +14 more
wiley +1 more source
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I [PDF]
, 2012 Background: Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity.
Ruimi, Nili +18 more
core +1 more source
Intensive Induction in AML in the Era of Venetoclax: A Standing Count for “7 + 3”?
American Journal of Hematology, EarlyView.
Sudhir Tauro, Ayalew Tefferi
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu +6 more
wiley +1 more source
[Acute lymphoblastic leukemia in children].
Revue medicale de Liege, 2005 We report our experience over the last seventeen years (1985-2002) of the treatment of acute lymphoblastic leukemia (ALL) in children at the University of Liege Pediatric Department of Hematogy-Oncology (CHU-Sart Tilman and CHR-Citadelle). Seventy seven children are enrolled in our study; the mean follow-up is 6.7 years.
Panizzotto, S +5 more
openaire +2 more sources
, 2009 Background Translocations of the Mixed Lineage Leukemia (MLL) gene occur in a subset (5%) of acute myeloid leukemias (AML), and in mixed phenotype acute leukemias in infancy - a disease with extremely poor prognosis.
Meyer, Claus +26 more
core +1 more source
Genetic Determinants of Treatment‐Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia
Clinical Pharmacology &Therapeutics, EarlyView.Osteonecrosis and fractures are serious corticosteroid‐induced bone toxicities in children treated for acute lymphoblastic leukemia, yet their genetic determinants remain incompletely defined. In this study, we aimed to identify novel genetic contributors to bone toxicity and to evaluate the robustness of both newly identified and previously ...
Rachid Abaji +14 more
wiley +1 more source